{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:52:27Z","timestamp":1779105147696,"version":"3.51.4"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T00:00:00Z","timestamp":1483660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol-Myers Squibb (Korea)"},{"name":"Bristol-Myers Squibb (Korea)"},{"name":"Bristol-Myers Squibb (Korea)"},{"name":"Bristol-Myers Squibb (Korea)"},{"name":"Bristol-Myers Squibb (Korea)"},{"name":"Bristol-Myers Squibb (Korea)"},{"name":"Bristol-Myers Squibb (Korea)"},{"name":"Bristol-Myers Squibb (Korea)"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0167770","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T20:33:19Z","timestamp":1483993999000},"page":"e0167770","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea"],"prefix":"10.1371","volume":"12","author":[{"given":"Do Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Hyub","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byungyool","family":"Jun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phil","family":"McEwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,1,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/liv.12108","article-title":"A nationwide seroepidemiology of hepatitis C virus infection","volume":"33","author":"DY Kim","year":"2013","journal-title":"South Korea. Liver Int"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2893.2011.01563.x","article-title":"Economic burden of hepatitis-C associated diseases in the United States","volume":"19","author":"AC El Khoury","year":"2012","journal-title":"J Viral Hepat"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3350\/cmh.2014.20.2.89","article-title":"KASL clinical practice guidelines: Management of Hepatitis C","volume":"20","year":"2014","journal-title":"Clin Mol Hepatol"},{"issue":"Suppl 2","key":"ref4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","article-title":"A systematic review of hepatitis C virus epidemiology in Asia","volume":"31","author":"W Sievert","year":"2011","journal-title":"Australia and Egypt. Liver Int"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/jmv.23661","article-title":"Clinical and epidemiological features of hepatitis C virus infection in South Korea: A prospective, multicenter cohort study","volume":"85","author":"MH Seong","year":"2013","journal-title":"J Med Virol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/17441692.2014.984742","article-title":"Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence","volume":"10","author":"DD Kim","year":"2015","journal-title":"Glob Public Health"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.26304","article-title":"The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States","volume":"58","author":"P McEwan","year":"2013","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/cid\/cit069","article-title":"Cost-effectiveness of screening for chronic hepatitis C infection in the United States","volume":"56","author":"MH Eckman","year":"2013","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep.25510","article-title":"Economic model of a birth cohort screening program for hepatitis C virus","volume":"55","author":"LJ McGarry","year":"2012","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/cid\/cis011","article-title":"Cost-effectiveness and population outcomes of general population screening for hepatitis C","volume":"54","author":"PO Coffin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.7326\/0003-4819-159-5-201309030-00672","article-title":"Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement","volume":"159","author":"VA Moyer","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1620\/tjem.215.33","article-title":"Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups","volume":"215","author":"J Nakamura","year":"2008","journal-title":"Tohoku J Exp Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1099\/00222615-47-7-643","article-title":"Distribution of genotypes in the 5\u2019 untranslated region of hepatitis C virus in Korea","volume":"47","author":"YS Park","year":"1998","journal-title":"J Med Microbiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000087258","article-title":"Epidemiology of hepatitis C virus in Korea","volume":"49","author":"HR Shin","year":"2006","journal-title":"Intervirology"},{"key":"ref15","unstructured":"Statistics Korea. South Korean population size 2014. Available at: http:\/\/kostat.go.kr\/<\/ext-link> [Accessed January 2015]."},{"key":"ref16","unstructured":"Health Insurance Review and Assessment Service (HIRA). HIRA claims data. Available at: http:\/\/www.hira.or.kr\/rd\/dissdic\/infoSickList.do?pgmid=HIRAA020044020200<\/ext-link> [Accessed January 2015]."},{"key":"ref17","unstructured":"2012 National Health Screening Statistical Yearbook. NHIC. Available from: http:\/\/kostat.go.kr\/<\/ext-link> [Accessed January 2015]"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3350\/cmh.2013.19.4.376","article-title":"Predicting factors of present hepatitis C virus infection among patients positive for the hepatitis C virus antibody","volume":"19","author":"CH Lee","year":"2013","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jmv.24335","article-title":"Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea","volume":"88","author":"SS Lee","year":"2016","journal-title":"J Med Virol"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"MS Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"ref21","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"ref22","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1","volume":"373","author":"DL Wyles","year":"2015","journal-title":"N Engl J Med"},{"key":"ref23","unstructured":"McPhee F, Wei L, Xie Q, Suzuki Y, Toyota J, Karino Y, et al. High SVR with DCV+ASV in HCV GT 1b Mainland Chinese, Koreans, and Taiwanese Without Baseline Resistance-Associated NS5A Polymorphisms. P-0102. Presented at APASL 2016."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"S638","DOI":"10.1016\/S0168-8278(15)31012-6","article-title":"P-0809: 98% SVR12 in Korean And Taiwanese patients with chronic genotype 2 HCV infection receiving 12 weeks of sofosbuvir plus ribavirin: Results from an international, multicenter phase 3 study","volume":"62","author":"JH J Kao","year":"2015","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options","volume":"368","author":"IM Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.26304","article-title":"The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States","volume":"58","author":"P McEwan","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"e0125846","DOI":"10.1371\/journal.pone.0125846","article-title":"Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections","volume":"10","author":"H Bennett","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/MEG.0000000000000510","article-title":"The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK","volume":"28","author":"P McEwan","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40258-012-0002-0","article-title":"Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model","volume":"11","author":"P McEwan","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"e0117334","DOI":"10.1371\/journal.pone.0117334","article-title":"Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C","volume":"10","author":"P McEwan","year":"2015","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.vhri.2013.08.001","article-title":"Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection","volume":"3","author":"P McEwan","year":"2014","journal-title":"Value in Health Regional Issues"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/hepr.12570","article-title":"Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b","volume":"46","author":"P McEwan","year":"2016","journal-title":"Hepatol Res"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jhep.2015.05.015","article-title":"Is antenatal screening for hepatitis C virus cost-effective? A decade's experience at a London centre","volume":"63","author":"N Selvapatt","year":"2015","journal-title":"J Hepatol"},{"key":"ref34","article-title":"The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit","author":"N Selvapatt","year":"2016","journal-title":"Liver Int"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.puhe.2016.08.002","article-title":"Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences","volume":"141","author":"T Ward","year":"2016","journal-title":"Public Health"},{"key":"ref36","article-title":"Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease","author":"T Ward","year":"2016","journal-title":"Clin Drug Investig"},{"key":"ref37","unstructured":"Statistics Korea. South Korean life tables. Available at: http:\/\/kostat.go.kr\/<\/ext-link> [Accessed January 2015]."},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1478-3231.2005.01062.x","article-title":"Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C","volume":"25","author":"F Imazeki","year":"2005","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2188\/jea.12.22","article-title":"The natural history model of hepatitis C virus infection and the economic evaluation of alpha interferon treatment","volume":"12","author":"K Hayashida","year":"2002","journal-title":"Journal of epidemiology \/ Japan Epidemiological Association"},{"key":"ref40","unstructured":"Korean Statistical Information Service (KOSIS). Consumer Price Index. 2016. Available from: http:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=101&tblId=DT_1J0A135&conn_path=I3<\/ext-link>http:\/\/kosis.kr\/<\/ext-link> [Accessed October 2016]."},{"key":"ref41","unstructured":"September 2016 exchange rate. http:\/\/fx.kebhana.com\/FER1201C.web?q=0AB6851A189E00DD4B01FBDFC80D027DDAADE24DCF611A;U77ZVkDIM3wM3KcoHHQwRcbzYHdkFFILnsJXLCdZJWVvQoApnjnMIt\/Ctcdx61Bo;XWCSRdX4yWyTVS8uZeEvlkQg5\/E%3D<\/ext-link>"},{"key":"ref42","unstructured":"Korean List Prices. [Accessed January 2015]."},{"key":"ref43","unstructured":"Ministry of Health and Welfare. National Health and Nutrition Examination Surveys (KNHANES) Report 2005."},{"key":"ref44","unstructured":"Health Insurance Review and Assessment Service (HIRA) claims data. Available from: http:\/\/www.hira.or.kr\/rd\/dissdic\/infoSickList.do?pgmid=HIRAA020044020200<\/ext-link> [Accessed January 2015]."},{"key":"ref45","article-title":"Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea","volume":"95","author":"DY Kim","year":"2016","journal-title":"Medicine"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Ishida H, Terai S, Sakaida I, Inoue Y. Cost-effectiveness of telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. The International Society for Pharmacoeconomics and Outcomes Research; 2012; Taipei, Japan.","DOI":"10.1016\/j.jval.2012.08.766"},{"key":"ref47","unstructured":"Okita K. Cost effectiveness of hepatocellular carcinoma treatment by disease stage: life expectancy and cost-effectiveness of single tumor by Markov model. Report of MHLW Urgent Measures Against Hepatitis Research Grant. 2007"},{"key":"ref48","unstructured":"International Monetary Fund. Korean gross domestic product per capita, current price. 2015. Available at: https:\/\/www.imf.org\/external\/pubs\/ft\/weo\/2015\/02\/weodata\/weorept.aspx?pr.x=82&pr.y=7&sy=2013&ey=2020&scsm=1&ssd=1&sort=country&ds=&br=1&c=542&s=NGDPDPC&grp=0&a=<\/ext-link>[Accessed October 2016]."},{"key":"ref49","unstructured":"Kim DY, Jun B, Kim TH, Park SH, Ward T, Webster S, et al. Clinical and Economic Outcomes of Treating Immediately with Daclatasvir Plus Asunaprevir Versus Delaying Treatment for HCV Patients in South Korea. Abstract. Korean Association for the Study of the Liver (KASL) 2015."},{"key":"ref50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1386-6346(99)00074-1","article-title":"Prevalence and risk factors of hepatitis C virus infection among Koreans in rural area of Korea","volume":"17","author":"HR Shin","year":"2000","journal-title":"Hepatol Res"},{"issue":"10","key":"ref51","first-page":"657","article-title":"Absenteeism and productivity among employees being treated for hepatitis C","volume":"17","author":"RA Brook","year":"2011","journal-title":"Am J Manag Care"},{"issue":"2","key":"ref52","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/hep.23726","article-title":"The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs","volume":"52","author":"J Su","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3111\/13696998.2011.566294","article-title":"The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities","volume":"14","author":"MD DiBonaventura","year":"2011","journal-title":"J Med Econ"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0167770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T09:30:17Z","timestamp":1568712617000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0167770"}},"subtitle":[],"editor":[{"given":"Sheng-Nan","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,6]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0167770","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,6]]}}}